Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press Careers
Contact Us
Company Logo
Reports Store
Top 11 Hot Markets
NEW
 Biologics Hot Titles 2025
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services
Recreation Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare
Mega Trends
3D Printing 5G and 6G Technologies Advanced Analytics and Predictive Analytics Alternative Proteins (Plant-Based, Cultured Meat) Artificial Intelligence (AI) Autonomous Systems Augmented Reality (AR) and Virtual Reality (VR) Big Data Analytics
Blockchain, Cryptocurrencies and Decentralized Finance (DeFi) Biotechnology Cloud Computing Cybersecurity Digital Therapeutics Digitalization E-commerce and Digital Retail Edtech and E-Learning
Electric Mobility ESG (Environmental, Social, Governance) Investments Fintech (Digital Payments, Neobanking, Open Banking) Healthtech and Telehealth Industry 4.0 and 5.0 Internet of Things (IoT) Nanotechnology Precision Medicine and Genomics
Quantum Computing Regtech and Insurtech Robotics Smart Homes and Buildings Space Economy Sustainability Sustainable Consumer Products Wearable Technology
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal

Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Report 2025

Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025 - By Type (IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types), By Molecule Type (Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types), By Route Of Administration (Oral, Parenteral, Subcutaneous, Topical), By Application (FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications) - Market Size, Trends, And Global Forecast 2025-2034

Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : June 2025 | Delivery Time: 2-3 business days Info | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures

Market Insights

Related Reports

What Is Covered Under Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Isocitrate Dehydrogenase (IDH) Inhibitors are a class of targeted cancer therapies designed to block the activity of mutated forms of the IDH1 and IDH2 enzymes. These enzymes are involved in cellular metabolism, and gene mutations can lead to abnormal cell growth and cancer development.

The main types of isocitrate dehydrogenase (IDH) inhibitors are IDH1 mutant medullary malignant tumor, IDH2 mutant medullary malignant tumor, and others. IDH1 mutant medullary malignant tumor refers to a type of cancerous growth that originates in the medullary (central) part of an organ or tissue and is characterized by a mutation in the IDH1 gene. It includes molecule types, such as Monoclonal Antibodies, peptides, small molecules, and others, and is administered through oral, parenteral, subcutaneous, and topical routes. It is used for applications such as FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and others.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Size and growth rate 2025 to 2029: Graph
Share Share

What Is The Isocitrate Dehydrogenase (IDH) Inhibitors Market Size 2025 And Growth Rate?

The isocitrate dehydrogenase (idh) inhibitors market size has grown exponentially in recent years. It will grow from $1.94 billion in 2024 to $2.46 billion in 2025 at a compound annual growth rate (CAGR) of 27.0%. The growth in the historic period can be attributed to increased incidence of hematologic cancers, improved genetic profiling in oncology, clinical success of targeted therapies, precision medicine initiatives, and rising healthcare spending in oncology.

What Is The Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Forecast?

The isocitrate dehydrogenase (idh) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $6.34 billion in 2029 at a compound annual growth rate (CAGR) of 26.7%. The growth in the forecast period can be attributed to supportive reimbursement policies, rising incidence of blood cancers, growing awareness among oncologists, increasing adoption of precision medicine, and a rise in healthcare infrastructure & oncology centers. Major trends in the forecast period include advances in genomic and molecular diagnostics, collaborations and licensing deals, advancements in drug delivery technologies, improvements in diagnostic technologies, and combination therapies development.

Book your 30 minutes free consultation with our research experts

Contact Us

How Is The Isocitrate Dehydrogenase (IDH) Inhibitors Market Segmented?

The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

What Is Driving The Isocitrate Dehydrogenase (IDH) Inhibitors Market? Increase In Acute Myeloid Leukemia Driving Growth Of The Market Due To Rising Incidence Among Aging And At-Risk Populations

The increase in the frequency of acute myeloid leukemia is expected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market going forward. Acute myeloid leukemia (AML) refers to a fast-growing cancer of the blood and bone marrow characterized by the rapid production of abnormal white blood cells that interfere with normal blood cell formation. The increase in the incidence of acute myeloid leukemia is due to the rise in the aging population as older adults face a higher risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors help treat acute myeloid leukemia by blocking mutant IDH enzymes, which restores normal blood cell development and slow the growth of leukemia cells. For instance, in February 2023, according to the report published by Leukaemia Foundation, an Australia-based non-profit organization, From 2022 to 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Therefore, an increase in the frequency of acute myeloid leukemia is expected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Who Are The Major Players In The Global Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

What Are The Key Trends Of The Global Isocitrate Dehydrogenase (IDH) Inhibitors Market? FDA Approves First Targeted Therapy For Grade 2 IDH-Mutant Glioma

Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are focusing on obtaining regulatory approvals to expand the clinical use of their therapies, accelerate market entry, and gain a competitive advantage in treating IDH-mutant cancers. Regulatory approvals refer to official permissions granted by health authorities that allow a drug to be marketed and used after confirming its safety and effectiveness. For instance, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly improves progression-free survival, as shown in the Phase 3 INDIGO trial, where patients had a median progression-free survival of 27.7 months versus 11.1 months for placebo. VORANIGO offers a convenient and well-tolerated option with manageable side effects, marking a significant advancement for a patient group with limited prior treatment choices.

What Are Latest Mergers And Acquisitions In The Isocitrate Dehydrogenase (IDH) Inhibitors Market? Novo Nordisk Expands Hemoglobinopathy Pipeline With Acquisition Of Forma Therapeutics

In October 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Forma Therapeutics for $1.1 billion. With this acquisition, Novo Nordisk aims to complement and accelerate its scientific presence and pipeline in hemoglobinopathies by expanding its portfolio to address sickle cell disease and other rare blood disorders. Forma Therapeutics is a US-based biopharmaceutical company focused on developing novel therapies for various cancers, including mutated isocitrate dehydrogenase (IDH) inhibitors.

What Is The Regional Outlook For The Global Isocitrate Dehydrogenase (IDH) Inhibitors Market?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Isocitrate Dehydrogenase (IDH) Inhibitors Industry?

The isocitrate dehydrogenase (IDH) inhibitors market research report is one of a series of new reports from The Business Research Company that provides isocitrate dehydrogenase (IDH) inhibitors market statistics, including isocitrate dehydrogenase (IDH) inhibitors industry global market size, regional shares, competitors with an isocitrate dehydrogenase (IDH) inhibitors market share, detailed isocitrate dehydrogenase (IDH) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (IDH) inhibitors industry. This isocitrate dehydrogenase (IDH) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Isocitrate Dehydrogenase IDH Inhibitors Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $2.46 billion
Revenue Forecast In 2034 $6.34 billion
Growth Rate CAGR of 26.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Isocitrate Dehydrogenase (IDH) Inhibitors Market Characteristics

    3. Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends And Strategies

    4. Isocitrate Dehydrogenase (IDH) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

    5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Growth Analysis And Strategic Analysis Framework

    5.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Rate Analysis

    5.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Total Addressable Market (TAM)

    6. Isocitrate Dehydrogenase (IDH) Inhibitors Market Segmentation

    6.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    IDH1 Mutant Medullary Malignant Tumor

    IDH2 Mutant Medullary Malignant Tumor

    Other Types

    6.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Monoclonal Antibodies

    Peptides

    Small Molecules

    Other Molecule Types

    6.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Parenteral

    Subcutaneous

    Topical

    6.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    FLT3 Inhibitor

    DH Inhibitor

    Hedgehog Pathway Inhibitor

    Other Applications

    6.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH1 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Acute Myeloid Leukemia (AML)

    Glioma Or Glioblastoma

    Cholangiocarcinoma

    Chondrosarcoma

    6.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH2 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Acute Myeloid Leukemia (AML)

    Myelodysplastic Syndromes (MDS)

    Angioimmunoblastic T-cell Lymphoma (AITL)

    6.7. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Solid Tumors with IDH Mutations

    Metastatic Cancers With IDH Alterations

    Experimental Or Off-label Uses In Rare Cancers

    7. Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional And Country Analysis

    7.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market

    8.1. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Isocitrate Dehydrogenase (IDH) Inhibitors Market

    9.1. China Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    9.2. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Isocitrate Dehydrogenase (IDH) Inhibitors Market

    10.1. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market

    11.1. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    11.2. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market

    12.1. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market

    13.1. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market

    14.1. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    14.2. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market

    15.1. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    15.2. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market

    16.1. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market

    17.1. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Isocitrate Dehydrogenase (IDH) Inhibitors Market

    18.1. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market

    19.1. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market

    20.1. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market

    21.1. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    21.2. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market

    22.1. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market

    23.1. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    23.2. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market

    24.1. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    24.2. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market

    25.1. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    25.2. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market

    26.1. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    26.2. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market

    27.1. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market

    28.1. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    28.2. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market

    29.1. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

    29.2. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape And Company Profiles

    30.1. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape

    30.2. Isocitrate Dehydrogenase (IDH) Inhibitors Market Company Profiles

    30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

    31. Isocitrate Dehydrogenase (IDH) Inhibitors Market Other Major And Innovative Companies

    31.1. Eli Lilly and Company

    31.2. Daiichi Sankyo Company Limited

    31.3. Les Laboratoires Servier

    31.4. Evotec SE

    31.5. HUTCHMED (China) Limited

    31.6. Rigel Pharmaceuticals Inc.

    31.7. CStone Pharmaceuticals

    31.8. Forma Therapeutics Holdings Inc.

    31.9. Philogen S.p.A.

    31.10. Kura Oncology, Inc.

    31.11. Philogen S.p.A.

    31.12. Agios Pharmaceuticals Inc.

    31.13. Adooq Bioscience LLC

    31.14. Taiho Pharmaceutical Co. Ltd.

    31.15. Celgene Corporation

    32. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Isocitrate Dehydrogenase (IDH) Inhibitors Market

    34. Recent Developments In The Isocitrate Dehydrogenase (IDH) Inhibitors Market

    35. Isocitrate Dehydrogenase (IDH) Inhibitors Market High Potential Countries, Segments and Strategies

    35.1 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2029 - Countries Offering Most New Opportunities

    35.2 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2029 - Segments Offering Most New Opportunities

    35.3 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH1 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH2 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Roche Holding AG Financial Performance
  • Table 79: Merck & Co., Inc. Financial Performance
  • Table 80: Bristol-Myers Squibb Company Financial Performance
  • Table 81: Novartis AG Financial Performance
  • Table 82: GlaxoSmithKline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH1 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH2 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Roche Holding AG Financial Performance
  • Figure 79: Merck & Co., Inc. Financial Performance
  • Figure 80: Bristol-Myers Squibb Company Financial Performance
  • Figure 81: Novartis AG Financial Performance
  • Figure 82: GlaxoSmithKline plc Financial Performance

Unlocking Opportunities in the Cardiovascular Health Supplements Market: Key Trends, Market Growth, and Forecast Insights

Read More

How the Cell Banking Outsourcing Market is Positioned for Growth: Trends, Market Size, and Future Opportunities (2025-2034)

Read More

Key Insights into the Cell Line Development Market: Trends, Growth Rate, and Opportunities Through 2034

Read More

Cell Therapy Human Raw Materials Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

Read More

Understanding Key Drivers and Growth Opportunities in the Cellulose Gel Market: Trends and Market Size Insights

Read More

Unlocking Opportunities in the Cholinergic Drugs Market: Key Trends, Market Growth, and Forecast Insights

Read More

How the Compound Camphor Ointment Market Will Grow: Key Trends, Market Size, and Opportunities Beyond 2025

Read More

Concierge Medicine Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Direct-Fed Microbials (DFM) Global Market Report 2025 – By Type (Bacillus Subtilis, Lactic Acid Bacteria, Bifidobacteria, Streptococcus Thermophilus, Other Bacteria), By Form (Liquid Form, Dry Form), By Livestock (Poultry, Swine, Ruminants, Aquatic Animals, Other Livestock) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Disposable Cutlery Global Market Report 2025 – By Type (Spoon, Fork, Knife), By Material (Plastic, Wood), By Sales Channel (Supermarkets, Hypermarkets, Convenience Stores, Specialty Stores, Discount Stores, E-Retail), By End User (Food Service Outlets, Institutional Food Services, Online Food Ordering) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Automotive Automatic Transmission Global Market Report 2025 – By Type (Automatic Transmission, Automated Manual Transmission, Dual Clutch Transmission, Continuously Variable Transmission), By Fuel Type (Gasoline, Diesel, Hybrid), By Vehicle Type (Passenger Cars, Light Commercial Vehicles, Heavy Commercial Vehicles) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Population Health Management Global Market Report 2025 – By Component (Software, Service), By Mode Of Delivery (On Premise, Cloud-Based), By End-User (Providers, Payers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Automotive Shock Absorber Global Market Report 2025 – By Type (Single-Tube Shock Absorbers, Twin-Tube Shock Absorbers), By Product Type (Hydraulic Type, Gas-Filled Type), By Technology (Air Shock Absorber, Damping Shock Absorber, Active, Semi-Active), By Sales Channel (Original Equipment Manufacturer (OEM), Aftermarket), By Application (Passenger Car, SUV Truck, Heavy Vehicle, Electric vehicle, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Isocitrate Dehydrogenase IDH Inhibitors market?

Isocitrate Dehydrogenase (IDH) Inhibitors are a class of targeted cancer therapies designed to block the activity of mutated forms of the IDH1 and IDH2 enzymes. These enzymes are involved in cellular metabolism, and gene mutations can lead to abnormal cell growth and cancer development. For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here

How will the Isocitrate Dehydrogenase IDH Inhibitors market drivers and restraints affect the market dynamics? What forces will shape the Isocitrate Dehydrogenase IDH Inhibitors industry going forward?

The Isocitrate Dehydrogenase IDH Inhibitors market major growth driver - Increase In Acute Myeloid Leukemia Driving Growth Of The Market Due To Rising Incidence Among Aging And At-Risk Populations. For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here

What is the forecast market size or the forecast market value of the Isocitrate Dehydrogenase IDH Inhibitors market?

The Isocitrate Dehydrogenase IDH Inhibitors market size has grown strongly in recent years. The isocitrate dehydrogenase (idh) inhibitors market size has grown exponentially in recent years. It will grow from $1.94 billion in 2024 to $2.46 billion in 2025 at a compound annual growth rate (CAGR) of 27.0%. The growth in the historic period can be attributed to increased incidence of hematologic cancers, improved genetic profiling in oncology, clinical success of targeted therapies, precision medicine initiatives, and rising healthcare spending in oncology. The isocitrate dehydrogenase (idh) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $6.34 billion in 2029 at a compound annual growth rate (CAGR) of 26.7%. The growth in the forecast period can be attributed to supportive reimbursement policies, rising incidence of blood cancers, growing awareness among oncologists, increasing adoption of precision medicine, and a rise in healthcare infrastructure & oncology centers. Major trends in the forecast period include advances in genomic and molecular diagnostics, collaborations and licensing deals, advancements in drug delivery technologies, improvements in diagnostic technologies, and combination therapies development. For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here

How is the Isocitrate Dehydrogenase IDH Inhibitors market segmented?

The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here

Which region has the largest share of the Isocitrate Dehydrogenase IDH Inhibitors market? What are the other regions covered in the report?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here.

Who are the major players in the Isocitrate Dehydrogenase IDH Inhibitors market?

Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC . For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here.

What are the key trends in the Isocitrate Dehydrogenase IDH Inhibitors market?

Major trends in the Isocitrate Dehydrogenase IDH Inhibitors market include FDA Approves First Targeted Therapy For Grade 2 IDH-Mutant Glioma. For further insights on the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here.

What are the major opportunities in the Isocitrate Dehydrogenase IDH Inhibitors market? What are the strategies for the Isocitrate Dehydrogenase IDH Inhibitors market?

For detailed insights on the major opportunities and strategies in the Isocitrate Dehydrogenase IDH Inhibitors market, request a sample here.

How does the Isocitrate Dehydrogenase IDH Inhibitors market relate to the overall economy and other similar markets?

For detailed insights on Isocitrate Dehydrogenase IDH Inhibitors's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Isocitrate Dehydrogenase IDH Inhibitors industry?

For detailed insights on the mergers and acquisitions in the Isocitrate Dehydrogenase IDH Inhibitors industry, request a sample here.

What are the key dynamics influencing the Isocitrate Dehydrogenase IDH Inhibitors market growth? SWOT analysis of the Isocitrate Dehydrogenase IDH Inhibitors market.

For detailed insights on the key dynamics influencing the Isocitrate Dehydrogenase IDH Inhibitors market growth and SWOT analysis of the Isocitrate Dehydrogenase IDH Inhibitors industry, request a sample here.